
sourcing the best research evidence in ophthalmology
Rho Kinase Elevated IOP Treatment (ROCKET) trials
February 1, 2018
Clinical trial
Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, Novack GD, Kopczynski CC.
Main finding: Netarsudil 0.02% was found to be non-inferior to timolol for the treatment of some patients with ocular hypertension and open-angle glaucoma.
- Purpose: To compare the efficacy and safety of the Rho kinase inhibitor netarsudil and timolol in Ocular Hypertension/Open-angle glaucoma
- Study type: Randomized controlled trial
- Condition: Open angle glaucoma, Ocular Hypertension
Participants: ≥18yo with bilateral OHT or OAG, IOP 21-26 at 1st visit and 18-26 at 2nd visit in at least 1 eye
- n=1167 (ROCKET-1 and 2 combined)
Intervention:
- Group 1: Netarsudil 0.02% daily
- Group 2: Netarsudil 0.02% bd
- Group 3: Timolol 0.5% bd
Netarsudil (od and bd dosing) was non-inferior to timolol in patients with maximum baseline IOP < 25 mm Hg
Outcomes | Netarsudil daily | Netarsudil bd | Timolol bd |
---|---|---|---|
Mean decrease from baseline IOP (mmHg) | 3.3-4.6 | 4.1-5.4 | 3.7-5.1 |
Reduction in IOP | 16-21% | 22-24% | 18-23% |
August 1, 2019
Clinical trial
Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.
Khouri AS, Serle JB, Bacharach J, Usner DW, Lewis RA, Braswell P, Kopczynski CC, Heah T.
Main finding: Netarsudil 0.02% was found to be non-inferior to timolol for the treatment of some patients with ocular hypertension and open-angle glaucoma.
- Purpose: To compare the efficacy and safety of the Rho kinase inhibitor netarsudil and timolol in Ocular Hypertension/Open-angle glaucoma
- Study type: Randomized controlled trial
- Condition: Open angle glaucoma, Ocular Hypertension
Participants: ≥18yo with bilateral OHT or OAG, IOP 21-26 at 1st visit and 18-26 at 2nd visit in at least 1 eye
- n=1167 (ROCKET-1 and 2 combined)
Intervention:
- Group 1: Netarsudil 0.02% daily
- Group 2: Netarsudil 0.02% bd
- Group 3: Timolol 0.5% bd
Follow up = 3 months
Netarsudil was noninferior to timolol in patients with baseline IOP <27 mm Hg and <30 mm Hg.
IOP lowering effect was sustained at 6 months.
The most common adverse effect was conjunctival hyperaemia (47.9%), mostly mild.
Outcomes | Netarsudil bd | Timolol bd |
---|---|---|
Mean decrease from baseline IOP (mmHg) | 3.9-4.7 | 3.8-5.2 |
Source Archive